PL4125842T3 - Równoczesne podawanie mirdametynibu i lifirafenibu do stosowania w leczeniu nowotworów - Google Patents
Równoczesne podawanie mirdametynibu i lifirafenibu do stosowania w leczeniu nowotworówInfo
- Publication number
- PL4125842T3 PL4125842T3 PL21721706.6T PL21721706T PL4125842T3 PL 4125842 T3 PL4125842 T3 PL 4125842T3 PL 21721706 T PL21721706 T PL 21721706T PL 4125842 T3 PL4125842 T3 PL 4125842T3
- Authority
- PL
- Poland
- Prior art keywords
- mirdametinib
- lifirafenib
- administration
- treating cancers
- cancers
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063005153P | 2020-04-03 | 2020-04-03 | |
| PCT/US2021/025551 WO2021202981A1 (en) | 2020-04-03 | 2021-04-02 | Co-administration of mirdametinib and lifirafenib for use in treating cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4125842T3 true PL4125842T3 (pl) | 2024-10-14 |
Family
ID=75674969
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21721706.6T PL4125842T3 (pl) | 2020-04-03 | 2021-04-02 | Równoczesne podawanie mirdametynibu i lifirafenibu do stosowania w leczeniu nowotworów |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US12667560B2 (pl) |
| EP (1) | EP4125842B1 (pl) |
| JP (2) | JP7748386B2 (pl) |
| KR (1) | KR20230048476A (pl) |
| CN (1) | CN116194095B (pl) |
| AU (1) | AU2021246141A1 (pl) |
| BR (1) | BR112022019914A2 (pl) |
| CA (1) | CA3174223A1 (pl) |
| CL (1) | CL2022002682A1 (pl) |
| CO (1) | CO2022015891A2 (pl) |
| DK (1) | DK4125842T3 (pl) |
| ES (1) | ES2985012T3 (pl) |
| FI (1) | FI4125842T3 (pl) |
| HU (1) | HUE067894T2 (pl) |
| IL (1) | IL296878A (pl) |
| MX (1) | MX2022012351A (pl) |
| PE (1) | PE20231211A1 (pl) |
| PL (1) | PL4125842T3 (pl) |
| PT (1) | PT4125842T (pl) |
| TW (1) | TWI893097B (pl) |
| WO (1) | WO2021202981A1 (pl) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL4125842T3 (pl) | 2020-04-03 | 2024-10-14 | Beigene, Ltd. | Równoczesne podawanie mirdametynibu i lifirafenibu do stosowania w leczeniu nowotworów |
| US20230293464A1 (en) * | 2022-03-17 | 2023-09-21 | SpringWorks Therapeutics Inc. | Treatment of pancreatic ductal adenocarcinoma with mirdametinib |
| MX2024011403A (es) * | 2022-03-17 | 2024-09-23 | Springworks Therapeutics Inc | Tratamiento con mirdametinib. |
| WO2023209611A1 (en) * | 2022-04-26 | 2023-11-02 | Beigene Switzerland Gmbh | Methods of treating cancer with a b-raf inhibitor, in particular lifirafenib |
| EP4601631A4 (en) * | 2022-10-14 | 2026-04-08 | Springworks Therapeutics Inc | COMBINATION INTENDED FOR USE IN CANCER TREATMENT |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004501190A (ja) | 2000-06-23 | 2004-01-15 | テバ ファーマシューティカル インダストリーズ リミティド | 治療薬の胃部保留および制御された放出のための急速膨張する組成物とその組成物を含む剤形 |
| AU7349801A (en) | 2000-07-19 | 2002-01-30 | Warner Lambert Co | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
| EP1562601A1 (en) | 2002-11-15 | 2005-08-17 | Warner-Lambert Company LLC | Combination chemotherapy comprising a mek inhibitor and capecitabine for treating cancer |
| KR101013932B1 (ko) | 2003-10-21 | 2011-02-14 | 워너-램버트 캄파니 엘엘씨 | Ｎ-[(ｒ)-2,3-디히드록시-프로폭시]-3,4-디플루오로-2-(2-플루오로-4-요오도페닐아미노)-벤자미드 다형체 형태 |
| WO2006061712A2 (en) | 2004-12-10 | 2006-06-15 | Pfizer Inc. | Use of mek inhibitors in treating abnormal cell growth |
| WO2006134469A1 (en) | 2005-06-14 | 2006-12-21 | Warner-Lambert Company Llc | Methods of preparing mek inhibitor |
| WO2007042885A2 (en) | 2005-10-07 | 2007-04-19 | Pfizer Products Inc. | Therapeutic combination comprising methotrexate and a specified inhibitor of mek1 and mek2 |
| TR201815685T4 (tr) | 2011-04-01 | 2018-11-21 | Genentech Inc | Kanser tedavisi için akt ve mek inhibe edici bileşiklerin kombinasyonları. |
| GB201320729D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| AU2016248376B2 (en) | 2015-04-15 | 2020-10-08 | Beone Medicines I Gmbh | Maleate salts of a B-RAF kinase inhibitor, crystalline forms, methods of preparation, and uses therefore |
| KR102811888B1 (ko) | 2017-09-08 | 2025-05-27 | 에프. 호프만-라 로슈 아게 | 암의 진단 및 치료 방법 |
| WO2019113345A1 (en) | 2017-12-06 | 2019-06-13 | Spyro Mousses | Combination of cancer therapeutics for treatment of cancer and hyperproliferative diseases |
| EP3560516A1 (en) | 2018-04-27 | 2019-10-30 | Bergen Teknologioverforing AS | Combination therapy including beta-sitosterol in combination with at least one of a braf inhibitor, a mek inhibitor or an erk inhibitor and methods and use thereof |
| US12208099B2 (en) | 2018-09-10 | 2025-01-28 | Mirati Therapeutics, Inc. | Combination therapies |
| PL4125842T3 (pl) | 2020-04-03 | 2024-10-14 | Beigene, Ltd. | Równoczesne podawanie mirdametynibu i lifirafenibu do stosowania w leczeniu nowotworów |
| US11066358B1 (en) | 2021-02-17 | 2021-07-20 | Warner-Lambert Company Llc | Compositions of essentially pure form IV of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof |
| US11571402B2 (en) | 2021-02-17 | 2023-02-07 | Springworks Therapeutics, Inc. | Dispersible formulations of N-((R)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof |
| US11084780B1 (en) | 2021-02-17 | 2021-08-10 | Springworks Therapeutics, Inc. | Crystalline solids of MEK inhibitor N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof |
| MX2024011403A (es) | 2022-03-17 | 2024-09-23 | Springworks Therapeutics Inc | Tratamiento con mirdametinib. |
| PE20242177A1 (es) | 2022-03-17 | 2024-11-07 | St Jude Childrens Res Hospital Inc | Tratamiento del glioma de bajo grado con mirdametinib |
-
2021
- 2021-04-02 PL PL21721706.6T patent/PL4125842T3/pl unknown
- 2021-04-02 ES ES21721706T patent/ES2985012T3/es active Active
- 2021-04-02 TW TW110112271A patent/TWI893097B/zh active
- 2021-04-02 CA CA3174223A patent/CA3174223A1/en active Pending
- 2021-04-02 FI FIEP21721706.6T patent/FI4125842T3/fi active
- 2021-04-02 JP JP2022560245A patent/JP7748386B2/ja active Active
- 2021-04-02 PT PT217217066T patent/PT4125842T/pt unknown
- 2021-04-02 DK DK21721706.6T patent/DK4125842T3/da active
- 2021-04-02 HU HUE21721706A patent/HUE067894T2/hu unknown
- 2021-04-02 PE PE2022002181A patent/PE20231211A1/es unknown
- 2021-04-02 AU AU2021246141A patent/AU2021246141A1/en active Pending
- 2021-04-02 KR KR1020227038490A patent/KR20230048476A/ko active Pending
- 2021-04-02 IL IL296878A patent/IL296878A/en unknown
- 2021-04-02 WO PCT/US2021/025551 patent/WO2021202981A1/en not_active Ceased
- 2021-04-02 US US17/995,002 patent/US12667560B2/en active Active
- 2021-04-02 EP EP21721706.6A patent/EP4125842B1/en active Active
- 2021-04-02 BR BR112022019914A patent/BR112022019914A2/pt unknown
- 2021-04-02 CN CN202180036587.XA patent/CN116194095B/zh active Active
- 2021-04-02 MX MX2022012351A patent/MX2022012351A/es unknown
-
2022
- 2022-09-30 CL CL2022002682A patent/CL2022002682A1/es unknown
- 2022-11-03 CO CONC2022/0015891A patent/CO2022015891A2/es unknown
-
2025
- 2025-06-18 JP JP2025102055A patent/JP2025120501A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230128315A1 (en) | 2023-04-27 |
| IL296878A (en) | 2022-12-01 |
| HUE067894T2 (hu) | 2024-11-28 |
| ES2985012T3 (es) | 2024-11-04 |
| CN116194095A (zh) | 2023-05-30 |
| EP4125842A1 (en) | 2023-02-08 |
| CO2022015891A2 (es) | 2023-05-08 |
| JP2023521036A (ja) | 2023-05-23 |
| EP4125842B1 (en) | 2024-06-05 |
| TWI893097B (zh) | 2025-08-11 |
| PT4125842T (pt) | 2024-08-06 |
| US12667560B2 (en) | 2026-06-30 |
| JP7748386B2 (ja) | 2025-10-02 |
| PE20231211A1 (es) | 2023-08-17 |
| MX2022012351A (es) | 2023-03-13 |
| DK4125842T3 (da) | 2024-07-22 |
| FI4125842T3 (fi) | 2024-08-06 |
| JP2025120501A (ja) | 2025-08-15 |
| CA3174223A1 (en) | 2021-10-07 |
| CL2022002682A1 (es) | 2023-06-16 |
| KR20230048476A (ko) | 2023-04-11 |
| CN116194095B (zh) | 2024-09-13 |
| AU2021246141A1 (en) | 2022-12-01 |
| TW202207910A (zh) | 2022-03-01 |
| BR112022019914A2 (pt) | 2022-12-13 |
| WO2021202981A1 (en) | 2021-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT4125842T (pt) | Coadministração de mirdametinibe e lifirafenibe para utilização no tratamento de cancros | |
| PT4181920T (pt) | Inibidor de kat6 e combinações para o tratamento do cancro da mama | |
| IL300067A (en) | Preparations and methods for the treatment of cancers | |
| IL277665A (en) | Heterocyclic inhibitors of MAT2A and methods of use for cancer therapy | |
| IL314346A (en) | Antibodies antagonistic to IL-18BP and their use in monotherapy and combination therapy in cancer treatment | |
| IL319269A (en) | Combination of DCC-3116 and MAPKAP pathway inhibitors for use in cancer treatment | |
| IL299950A (en) | Superantigen conjugate for use in methods and compositions for the treatment of cancer | |
| IL295088B2 (en) | Compounds and preparations for use in the treatment of skin disorders | |
| GB202014736D0 (en) | Novel compounds and their use in therapy | |
| ZA202307970B (en) | Compounds for use in the treatment and prevention of covid- 19 | |
| SMT202500434T1 (it) | Sotorasib per l'uso nel trattamento del cancro | |
| IL285171B2 (en) | Treatment of skin lesions and itching in patients with PRURIGO NODULARIS | |
| GB202314118D0 (en) | Methods of classifying and treating patients | |
| EP4445914A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF TUMORS AND USE | |
| IL321393A (en) | CTPS1 inhibitors for use in the treatment of cancers with CTPS2 deficiency | |
| IL314316A (en) | Compounds and their use in cancer treatment | |
| HUE070513T2 (hu) | Rákos megbetegedések szekvenciális kezelése 6-tio-DG és checkpoint-inhibitorok alkalmazásával | |
| PL4294395T3 (pl) | Leczenie raka sutka za pomocą terapii skojarzonych zawierających GDC-9545 i GDC-0077 | |
| IL299039A (en) | Methods and preparations for the treatment of triple-negative breast cancer | |
| IL319234A (en) | Pyrazolylsulfonamide compounds and their use in therapy | |
| EP4422547A4 (en) | DEVICES AND METHODS FOR THE TREATMENT OF ORAL TISSUE | |
| IL313763A (en) | Antibodies against SARS-CoV-2 SPIKE (S) and their use in the treatment of COVID-19 | |
| GB202101728D0 (en) | Compounds and their use treating cancer | |
| GB202302820D0 (en) | ProC3 and TGFBI in cancer | |
| IL286699A (en) | Atypical protein c kinase inhibitors and their use in the treatment of hedgehog pathway-dependent cancers |